CompletedNCT00796185

As Study of the Pharmacokinetics of Paliperidone Extended-release and Risperidone Immediate-release Formulations

Medication studyAges 18–50Schizophrenia

The study in practice

Understand this study

This study was for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.

Study clarity

Study start dateAugust 2003

Recruitment status: Completed
Enrollment listed in the registry: 62
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Sponsor type: Pharmaceutical company
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 1
Locations: Not clearly listed
Age range: From 18 Years to 50 Years
Official registry ID: NCT00796185
Official title: Show the full official title
Comparison of Steady-state Pharmacokinetics of Paliperidone After Extended-release OROS� Paliperidone 15 mg and Immediate-release Oral Risperidone 8 mg b.i.d. in Subjects With Schizophrenia or Schizoaffective Disorder

Completed

Locations not listed

FAQ

Who is behind this study?

The study sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including Paliperidone ER.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.